Certifications are now available!
Chairs: N. Tsoukalas, D. Papageorgiou
10.00-10.30 Abstract 12000 E. Makraki
Dexamethasone reduction or omission with NEPA and
olanzapine for HEC: A phase III trial
Abstract LBA12003
Nationwide randomized, phase III, placebo-controlled trial of
bupropion for cancer-related fatigue: Primary outcome results.
10.30-11.00 Abstract 12010 A. Pelteki
Effect of a weight loss intervention (WLI) on quality of
life (QOL) and symptoms in women with breast cancer:
Results from the Breast Cancer Weight Loss (BWEL) trial.
Abstract LBA12008
SUPPORT+ digital self management and clinical support
for advanced cancer: A randomized controlled trial.
11.00-11.20 Discussants: Ν. Tsoukalas, D. Papageorgiou
Chairs: A. Kotsakis, V. Lachanas
11.20-11.50 Abstract 6000 P. Katsaounis
Adjuvant radiotherapy versus observation following
curative surgery for early-stage oral squamous
cell carcinoma (AREST; TRI/2017/07/009114).
Abstract 6004
Carboplatin-based versus cisplatin-based induction-concurrent
chemoradiotherapy with locoregionally advanced
nasopharyngeal carcinoma: A multicenter, parallel-group,
non-inferiority, randomized, phase 3 trial.
11.50-12.20 Abstract 6008 M. Drizou
Amivantamab in HPV-unrelated recurrent/metastatic
head and neck squamous cell cancer after disease
progression on immune checkpoint inhibitor and chemotherapy:
Pivotal results from the phase 1b/2 OrigAMI-4 study
Abstract 6011
Trastuzumab deruxtecan in patients with HER2-low recurrent/
metastatic salivary gland carcinoma: Results from
the phase II MYTHOS trial.
12.20-12.35 Discussant A. Psyrri
12.35-13.05 Abstract LBA6007 A. Kokkalis
Ultra-low-dose immunotherapy plus oral metronomic
chemotherapy versus paclitaxel-carboplatin in
platinum-sensitive recurrent or metastatic head and
neck squamous cell carcinoma: A randomized phase III trial.
Abstract 6002
Metronomic adjuvant chemotherapy (MACE) in
locally advanced oral cavity squamous cell carcinoma
post-surgery and adjuvant treatment (MACE postop):
A phase III randomized controlled trial.
13.05-13.20 Discussant G. Gomatou
Chairs: C. Panopoulos, E. Kontopodis
14.20-14.40 Abstract 2502 G. Karkaletsos
DART (NCI/SWOG S1609): Comprehensive results from
dual checkpoint inhibition with CTLA-4 and
PD-1 blockade in rare cancers
Abstract 3143 A. Lazarou
Can GLP-1 receptor agonists mitigate cancer progression?
A propensity-matched analysis across seven solid tumors.
14.40-15.00 Telisotuzumab-Vedotin (Teliso-V) for locally
advanced or metastatic non-squamous NSCLC
Zongertinib and Sevabertinib for HER2-mutant
Non-Squamous (NSCLC)
15.00-15.20 Discussant E. Kontopodis
Chairs: S. Labropoulos, C. Kosmas
15.20-15.35 Abstract LBA2000 D. Kalapanida
Final results of a randomized, controlled, phase 3 trial
comparing resection and post-operative stereotactic
radiation versus resection and cesium-131 tile-based
radiation for treatment of newly diagnosed brain metastases.
15.35-15.45 Discussant E. Kontopodis
Chairs: E. Lalla, E. Saloustros
15.45-16.00 Abstract 500 K. Rapti
First results from the OPTIMA phase III randomized
non-inferiority trial of test-directed chemotherapy in
patients with high clinical risk ER-positive HER2-negative
early breast cancer
16.00-16.10 Discussant E. Saloustros
16.10-16.25 Abstract LBA503 S. Douvetzemis
Omission of completion axillary dissection in patients
with breast cancer and sentinel lymph node macrometastases:
Overall survival and patient-reported arm morbidity from
the randomized SENOMAC trial.
16.25-16.35 Discussant: M. Kontos
Chairs: V. Barbounis, E. Galani
17.15-17.45 Abstract 1005 C. Aidarinis
Efficacy and safety of tucatinib (TUC) vs placebo (PBO)
combined with trastuzumab and pertuzumab (HP) as
maintenance therapy for HER2+ metastatic breast cancer
by stratified subgroups.
Abstract LBA1006
Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) +
PALBO as first-line (1L) therapy in patients (pts) with
estrogen receptor–positive, HER2-negative locally advanced
or metastatic breast cancer (ER+, HER2– LA/mBC): Primary
analysis of the phase III persevERA BC trial.
17.45-18.15 Abstract LBA1007 N. Asimakopoulou
First-line (1L) camizestrant (CAMI) for emergent ESR1
mutations (ESR1m) in advanced breast cancer (ABC):
Final progression-free survival 2 (PFS2) from
the Phase III SERENA-6 trial.
Abstract LBA1000
Progression-free survival after next line of treatment (PFS2)
and subsequent therapies (subs tx) in the ASCENT-04 study of
participants (pts) with previously untreated PD-L1+ metastatic
triple-negative breast cancer (mTNBC) treated with sacituzumab
govitecan (SG) plus pembrolizumab (pembro) vs
chemotherapy (chemo) plus pembro.
Chairs: E. Kontopodis, I. Samaras
09.00-09.30 Abstract 102 A. Markou
Benefit of adjuvant chemotherapy in resected
stage I-IV CRC patients based on ctDNA dynamics
across two timepoints: Results from GALAXY study.
Abstract LBA3503
BREAKWATER: Progression-free and overall survival
analyses of first-line (1L) encorafenib +
cetuximab (EC) + FOLFIRI in BRAF V600E-mutant
metastatic colorectal cancer (mCRC).
Chairs: P. Papakostas, I. Samaras
09.30-10.00 Abstract LBA4000
Efficacy and safety results from EMERALD-3: A phase 3,
randomized study of tremelimumab plus durvalumab with
or without lenvatinib combined with transarterial
chemoembolization (TACE) in participants (pts) with
embolization-eligible unresectable hepatocellular
carcinoma (HCC).
Abstract LBA5 Μ. Avgoustidou
Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs
chemotherapy in previously treated patients with
metastatic pancreatic adenocarcinoma (mPDAC):
Primary analysis from the phase 3 RASolute 302 study.
10.00-10.10 Discussant G. Papaxoinis
Chairs: Η. Gogas, V. Georgoulias
10.40-11.10 Abstract LBA9505 A. Laskarakis
Updated Outcomes from STAMP: Surgically Treated
Adjuvant Merkel Cell Carcinoma with Pembrolizumab,
a Phase III Trial: ECOG-ACRIN EA6174.
Abstract 9518
A 3-year landmark overall survival analysis of RP1 plus
nivolumab in patients with anti–PD-1–failed melanoma
from the IGNYTE clinical trial.
11.10-11.40 Abstract LBA9503 I. Gazouli
Darovasertib in combination with crizotinib versus investigator’s
choice as first-line treatment for patients with HLA-A2–negative
metastatic uveal melanoma: Results from
the phase 2/3 OptimUM-02 study.
11.40-12.00 Discussant H. Gogas
Chairs: M. Nikolaou, E. Saloustros
12.00-12.30 Abstract LBA100 D. Timplalexi
NHS-Galleri: Primary results from a randomised controlled trial
to assess the clinical utility of a multi-cancer early detection
(MCED) test in population screening
Abstract 10515
Low-dose tamoxifen for pre-cancer and early disease:
A pooled analysis by menopausal status.
12.30-12.40 Panel Discussion
Chairs: R. Zakopoulou, O. Fiste
12.40 -13.10 Abstract 5505 A. Pantazopoulos
HRONO: A randomized phase II trial of the chronology of
surgery after neoadjuvant chemotherapy for ovarian cancer.
Abstract 5506
A randomized phase II trial of mirvetuximab soravtansine in
folate receptor alpha (FRα)–high recurrent ovarian cancer
eligible for platinum-based chemotherapy
(MIROVA/AGO-OVAR 2.34).
Abstract 5517
Effects of short-term fasting compared to free diet in
ovarian cancer patients: Results from a two-arm pilot
randomized trial.
13.10-13.20 Discussant M. Rovithi
Chairs: F. Dimitrakopoulos, A. Boutis
14.20-15.10 Abstract LBA3 G. Christodoulopoulos
Event-Free Survival with Adjuvant Selpercatinib in Stage
IB-IIIA RET Fusion-Positive NSCLC: Primary Results of
the Phase 3 LIBRETTO-432 Trial
Abstract 8000
Randomized phase III study of nivolumab after surgery
and adjuvant chemotherapy in NSCLC
(ECOG-ACRIN EA5142, ALCHEMIST).
Abstract 8006
Intracranial efficacy of tarlatamab versus chemotherapy (CTx)
as second-line (2L) treatment for small cell lung cancer (SCLC):
DeLLphi-304 phase 3 post hoc analysis.
Abstract 8004
Redefining lung cancer screening eligibility: Smoking duration
vs. pack-years in a national VA cohort of nearly 1 million patients
15.10 -15.30 Discussant A. Grivas
Chairs: A. Kotsakis, G. Gomatou
15.30-16.00 Abstract LBA4 T. Tegos
Ivonescimab plus chemotherapy versus tislelizumab plus
chemotherapy in previously untreated advanced squamous
non–small cell lung cancer: Overall survival results of
the phase 3 HARMONi-6 trial.
Abstract LBA8500
Sunvozertinib monotherapy versus platinum-based chemotherapy
as first-line treatment for advanced NSCLC with EGFR exon20ins:
Primary analysis of a multinational phase 3 randomized study
(WU-KONG28).
16.00-16.15 Abstract 8506 S. Talagani
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P)
versus pembrolizumab (P) as first-line treatment for
PD-L1–positive advanced non-small cell lung cancer
(NSCLC): Results from the randomized phase 3
OptiTROP-Lung05 study.
16.15-16-35 Discussant O. Fiste
Chairs: A. Koumarianou, A. Boutis
15.20-15.40 Presenter: E.-G. Fergadis
Abstract 8006: Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
Abstract LBA8008: Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial.
15.40-15.50 Presenter: A. Pantazopoulos
Abstract 8001: Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
15.50-16.10 Discussant: A. Grivas
Chairs: M. Tsiatas, F. Koinis
17.10-17.40 Abstract 10503 S. Chrysoglou
Effect of type and location of BRCA2 deleterious variant on
prognosis and survival in metastatic prostate cancer:
A longitudinal, international, cohort study from
hormone-sensitive to castration-resistant settings.
Abstract LBA1
Perioperative (neoadjuvant and adjuvant) apalutamide (APA) +
androgen deprivation therapy (ADT) vs placebo (PBO) + ADT
with radical prostatectomy (RP) in high-risk localized or
locally advanced prostate cancer (HR LPC/LAPC):
Final analysis of the PROTEUS phase 3 study.
17.40-18.10 Abstract 5005 E. Christakou
Cognitive effects of darolutamide vs enzalutamide:
Results of ARACOG (AFT-47), a randomized clinical trial
from the Alliance for Clinical Trials in Oncology.
Abstract 108
An AI-based pathology classifier to predict benefit from
enzalutamide in metastatic hormone-sensitive prostate
cancer (mHSPC) from ENZAMET (ANZUP 1304).
18.10-18.30 Discussant M. Tsiatas
18.30-19.00 Abstract 5001 N. Cholis
Assessment of the ability of Decipher Prostate Genomic Classifier
(DGC) >0.85 to identify patients who benefit from adding
docetaxel (DOC) to androgen deprivation therapy (ADT)
plus enzalutamide (ENZ): Level 1B evidence from
the ENZAMET study.
Abstract 4504
Feasibility and safety results from RAD-IO: A multi-stage trial
of durvalumab with chemoradiotherapy with 5-fluorouracil and
mitomycin C in patients with muscle-invasive bladder cancer.
Abstract 4507
Enfortumab vedotin plus pembrolizumab (EV+P) vs
chemotherapy for previously untreated locally advanced
or metastatic urothelial carcinoma (la/mUC): 3.5-year
follow-up and response analyses from the phase 3 EV-302 study.
19.00-19.20 Discussant E. Lianos
Chairs: I. Boukovinas, S. Kokkali
19.20-19.50 Abstract LBA2 A. Zazas
SARC041: A phase 3 randomized double-blind study of
abemaciclib versus placebo in patients with advanced
dedifferentiated liposarcoma.
Abstract 11506
RINGSIDE: A phase 3 randomized, placebo-controlled trial
of varegacestat for treatment of progressing esmoids tumors.
Abstract 11500
Primary results of the phase 3 peak study of bezuclastinib +
sunitinib vs sunitinib monotherapy in advanced
gastrointestinal stromal tumors (GIST).
19.50-20.10 Discussant S. Kokkali
